Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhaled Medications

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...

Oral Drug Delivery Systems: Introduction

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of High Dose Oseltamivir Phosphate Dry Powder for Inhalation Therapy in Viral Pneumonia.

Pharmaceutics·2020

Same author

Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.

International journal of pharmaceutics·2017

Same author

The influence of high shear mixing on ternary dry powder inhaler formulations.

International journal of pharmaceutics·2017

Same author

Nano- and Microstructured model carrier surfaces to alter dry powder inhaler performance.

International journal of pharmaceutics·2016

Same author

Applicability of the one-step DVS method for the determination of amorphous amounts for further different hydrophilic and hydrophobic drugs.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2015

Same author

Measurement of low amounts of amorphous content in hydrophobic active pharmaceutical ingredients with dynamic organic vapor sorption.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2015

Search research articles

Related Experiment Video

Updated: Apr 26, 2026

Intratracheal Administration of Dry Powder Formulation in Mice

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

Formulation considerations for dry powder inhalers.

Eike Cordts¹, Hartwig Steckel

¹Department of Pharmaceutics & Biopharmaceutics, Kiel University, Gutenbergstrasse 76, 24118 Kiel, Germany.

Therapeutic Delivery

|August 5, 2014

Summary

This review covers key considerations for developing dry powder inhaler systems. It highlights the growing market for lung-targeted drug delivery, both for respiratory diseases and systemic treatments.

Area of Science:

Pharmaceutical Sciences
Pulmonary Drug Delivery
Medical Device Development

Background:

The market for dry powder inhalers (DPIs) is expanding, driven by the advantages of lung-targeted drug delivery over oral administration.
Inhalation products have advanced local respiratory disease treatment and enabled systemic drug delivery via the lungs.
DPI development is complex, involving intricate drug formulation and inhalation device interactions.

Purpose of the Study:

To provide a comprehensive overview of essential considerations for successful dry powder inhaler development.
To guide researchers and developers in navigating the complexities of DPI systems.
To consolidate knowledge on optimizing DPIs for both local and systemic drug delivery.

Main Methods:

More Related Videos

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Apr 26, 2026

Intratracheal Administration of Dry Powder Formulation in Mice

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

This review synthesizes existing literature and industry best practices.

It analyzes the interplay between drug formulation characteristics and device design.

Key developmental challenges and solutions are discussed.

Main Results:

Successful DPI development requires careful attention to formulation stability, particle engineering, and device-user interface.
Optimizing aerosol performance is critical for efficient lung deposition.
Understanding the specific therapeutic need (local vs. systemic) informs design choices.

Conclusions:

A multidisciplinary approach is crucial for effective dry powder inhaler development.
Addressing formulation-device synergy is paramount for therapeutic success.
This review offers a foundational guide for advancing DPI technology and applications.